Download PDF
Thromb Haemost 2015; 113(01): 217-220
DOI: 10.1055/s-0037-1608992
Editors’ Choice
Schattauer GmbH

Editors’ Choice papers in Thrombosis and Haemostasis

Christian Weber
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
2   DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
,
Gregory Y. H. Lip
3   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 De Caterina R, Husted S, Wallentin L. et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Husted S, de Caterina R, Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Rubboli A, Faxon DP, Airaksinen KEJ. et al. The optimal management of patients on oral antico-agulation undergoing coronary artery stenting. The 10th Anniversary Overview. Thromb Hae-most 2014; 112: 1080-1087.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014; 111: 189-198.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with endstage renal disease. Thromb Haemost 2013; 109: 596-605.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Douxfils J, Chatelain C, Chatelain B. et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Hae-most 2013; 110: 283-294.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Gouin-Thibault I, Flaujac C, Delavenne X. et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Hae-most 2014; 111: 240-248.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Douxfils J, Dogne J-M, Mullier F. et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-549.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Hapgood G, Butler J, Malan E. et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the He-moclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110: 308-315.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Mani H, Hesse C, Stratmann G. et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Hae-most 2013; 109: 127-136.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Douxfils J, Tamigniau A, Chatelain B. et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Pisters R, Nieuwlaat R, Lane DA. et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013; 109: 328-336.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Skjoth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabi-gatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparisonanalysis.ThrombHaemost 2014; 111: 981-988.
    PubMedGoogle Scholar
  • 16 Lowres N, Neubeck L, Redfern J. et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-217.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Lowres N, Neubeck L, Salkeld G. et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-1176.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Roldan V, Marin F, Manzano-Fernandez S. Does chronic kidney disease improve the predictive value of the CHADS(2) and CHA(2)DS(2)-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 2013; 109: 956-960.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Apostolakis S, Lane D, Buller H. Comparison of the CHADS(2),CHA(2)DS(2) -VASc and HASBLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with at-rial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110: 1074-1079.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Gallego P, Roldan V, Marín F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. ThrombHaemost 2013; 110: 1189-1198.
    PubMedGoogle Scholar
  • 21 Cattaneo M. High on-treatment platelet reactivity - definition and measurement. Thromb Haemost 2013; 109: 792-798.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Saucedo JF, Angiolillo DJ, DeRaad R. et al. SWAP Investigators. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Hohlfeld T, Saxena A, Schroer K. High on treatment platelet reactivity against aspirin by non-ste-roidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance. Thromb Hae-most 2013; 109: 825-833.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Dahlen J, Price M, Parise H. et al. Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thromb Haemost 2013; 109: 808-816.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Grove E, Hossain R, Storey R. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Serebruany V, Fortmann S. Viewpoint: “Under-utilisation of novel antiplatelet agents - myths, generics, and economics". Thromb Haemost 2014; 112: 4-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Langer HF, Weber C, Gawaz M. The platelet-thrombosis and beyond. Thromb Haemost 2013; 110: 857-858.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894-902.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Blanchet X, Cesarek K, Brandt J. et al. Inflammatory role and prognostic value of platelet chemo-kines in acute coronary syndrome. Thromb Hae-most 2014; 112: 1277-1287.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Necchi V, Balduini A, Noris P. et al. Ubiquitin/pro-teasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia. Thromb Haemost 2013; 109: 263-271.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Aradi D, Komócsi A, Vorobcsuk A. et al. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analy-sis. Thromb Haemost 2013; 109: 93-101.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Quinderé AL, Benevides NM, Carbone F. et al. Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrom-bosis. Thromb Haemost 2014; 111: 634-646.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 de Boer OJ, Li X, Teeling P. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 2013; 109: 290-297.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Andrews RK, Arthur JF, Gardiner EE. Neutrophil extracellular traps (NETs) and the role of platelets in infection. Thromb Haemost 2014; 112: 659-665.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Geddings JE, Mackman N. New players in haemo-stasis and thrombosis. Thromb Haemost 2014; 111: 570-574.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013; 109: 416-420.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Carestia A, Rivadeneyra L, Romaniuk MA. et al. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb Haemost 2013; 110: 1035-1045.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost 2013; 109: 399-406.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Goddard LM, Iruela-Arispe ML. Cellular and molecular regulation of vascular permeability. Thromb Haemost 2013; 109: 407-415.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Ehling J, Lammers T, Kiessling F. Non-invasive imaging for studying anti-angiogenic therapy effects. Thromb Haemost 2013; 109: 375-390.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost 2013; 109: 391-398.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Asare Y, Shagdarsuren E, Schmid JA. et al. En-dothelial CSN5 impairs NF-kB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 2013; 110: 141-152.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Manthey HD, Cochain C, Barnsteiner S. et al. CCR6 selectively promotes monocyte mediated inflammation and atherogenesis in mice. Thromb Haemost 2013; 110: 1267-1277.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Roldán V, Arroyo AB, Salloum-Asfar S. et al. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost 2014; 112: 781-788.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Kaudewitz D, Lee R, Willeit P. et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110: 609-615.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Badrnya S, Baumgartner R, Assinger A. Smoking alters circulating plasma microvesicle pattern and microRNA signatures. Thromb Haemost 2014; 112: 128-136.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Nencioni A, da Silva RF, Fraga-Silva RA. et al. Ni-cotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014; 111: 308-322.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Vaezzadeh N, Ni R, Kim PY. et al. Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. Thromb Haemost 2014; 112: 412-418.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Xu Y, Cai TQ, Castriota G. et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014; 111: 694-704.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Lei X, Reheman A, Hou Y. et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014; 111: 279-289.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Nieuwenhuizen L, Roosendaal G, Mastbergen SC. et al. Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice. Thromb Hae-most 2014; 112: 1044-1050.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Orriols M, Guadall A, Galán M. et al. Lysyl oxidase (LOX) in vascular remodelling. Insight from a new animal model. Thromb Haemost 2014; 112: 812-824.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Sala F, Aranda JF, Rotllan N. et al. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost 2014; 112: 796-802.
    Article in Thieme ConnectPubMedGoogle Scholar